ArticleMaterials today. Bio2025
Hybrid biomaterials-based radiosensitizers: Preparations and their applications in enhancing tumor radiotherapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges.International journal of molecular sciences · 2026Pooled it
- PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy.Materials today. Bio · 2026Article
- Exosome-loaded nanoradiosensitizers in radiotherapy for preventing post-irradiation tumor recurrence: mechanisms, preclinical evidence, and translational challenges.Discover nano · 2026Review
- Current Perspectives on Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2026Review
- Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is a critical modality in cancer treatment, yet its efficacy can be substantially hindered by the tumor microenvironment. Nanotechnology has empowered nanomaterials to assume multifunctional roles. These roles encompass drug delivery, radiosensitization, imaging, inducing DNA damage, and decreasing glutathione (GSH) levels to impede the neutralization of reactive oxygen species (ROS), thus enhancing therapeutic efficacy. Consequently, hybrid materials integrating multiple functional components have garnered significant attention. In recent years, the development of hybrid biomaterials-based radiosensitizers has successfully addressed these challenges and attracted considerable interest. This review systematically summarizes the synthesis methods, composition, and potential applications of hybrid biomaterials-based radiosensitizers in radiotherapy. The synthesis techniques are classified into self-assembly, chemical synthesis, and biomimetic synthesis. Furthermore, we examine various types of inorganic, inorganic-organic, and organic hybrid biomaterials-based radiosensitizers, with an emphasis on their mechanisms of action, including enhancing ionizing radiation effects, alleviating tumor hypoxia, and depleting GSH. Finally, we discuss the future prospects and existing challenges of hybrid biomaterials-based radiosensitizers in cancer therapy, highlighting their potential to markedly improve therapeutic efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.